This segment focuses on developing and commercializing rapid, point-of-care pharmacogenetic tests, enabling personalized medicine approaches. Key activities include research and development of novel assays, clinical trials to validate test performance, and regulatory approvals for commercialization. The Genedrive CYP2C19-ID Kit is a key product in this segment, used to identify gene mutations that affect drug metabolism, particularly for antiplatelet drugs like clopidogrel. This allows clinicians to tailor drug prescriptions to individual patients, reducing the risk of adverse events and improving treatment outcomes. Future opportunities include expanding the range of pharmacogenetic tests offered and integrating them into routine clinical practice.

This segment is dedicated to the development and commercialization of molecular diagnostic solutions for infectious diseases. Research and development efforts focus on creating rapid, accurate, and cost-effective tests for various pathogens, including Hepatitis C Virus (HCV). The Genedrive HCV ID Kit is a key product, offering a qualitative molecular solution for HCV testing, particularly in decentralized settings. The company collaborates with organizations like FIND to evaluate and improve the performance of these diagnostic kits. Future growth potential lies in expanding the range of infectious disease targets and developing multiplex assays for simultaneous detection of multiple pathogens.